ABSTRACT
Objective: To study the efficacy and safety of the intrapleural injection of nedaplatin combined with recombinant hu-man endostatin (Endostar) in the treatment of malignant pleural effusion in non-small cell lung cancer (NSCLC) patients. Methods:Seventy patients diagnosed with NSCLC with malignant pleural effusion were treated by intrapleural injection. The subjects were divid-ed into two groups, as follows: 35 cases were injected with nedaplatin and Endostar (the treatment group) and 35 cases were injected with nedaplatin only (the control group). One month after the treatment, the clinical efficacy and toxicity were evaluated. The clinical ef-ficacy, quality of life, and toxic reaction were compared between the two groups. Results: The short-term clinical efficacy rate of the treatment group was 74.28%, whereas that of the control group was 48.57%, and the difference between the two groups was significant (P0.05). Conclusion: The efficacy of the intrapleural injection of recombinant human endostatin combined with nedaplatin is superior to that of cisplatin alone in the treatment of malignant pleural effusion, without increasing chemotherapeutic toxicity.
ABSTRACT
Objective:To determine the relationship among tumor malignancy, invasion, and plasma D-dimer (DD) levels via a retrospective analysis of the correlation between preoperative plasma DD levels and postoperative pathology parameters in esophageal cancer patients. Methods:A total of 101 esophageal cancer patients without coagulation among preoperative plasma DD levels and postoperative pathology parameters in esophageal cancer patients who underwent radical operation between January 2009 to April 2010 were enrolled. The preoperative plasma DD levels, postoperative pathology T, N Grade, number of metastatic lymph nodes, tumor posi-tion, tumor length, and TNM stage were recorded. A statistic analysis of the above parameters was performed to reveal the correlation between plasma DD levels and tumor pathology features. Results:Preoperative plasma DD level has no correlation with Grade and tu-mor length, but shows positive correlation with pathology T, N status, and TNM stage, and has strong positive correlation with numbers of metastatic nodes. In addition, lower-third thoracic esophageal cancer patients have higher DD level than middle-third thoracic cases. Conclusion:Plasma DD level has a positive correlation with T stage, N stage, TNM stage, and number of positive lymph nodes. It also has important clinical significance.
ABSTRACT
Objective To prepare and identify monoclonal antibodies (mAb) against histidine-tag (His-tag ) .Methods Balb/c mice were immunized with polypeptides containing 15 histindine(His)-coupled BSA and this fusion was prepared according to con-ventional methods .Indirect ELISA was used to screen the positive clones and limited dilution for further cloning .After purified with Protein G affinity chromatography ,these antibodies for His-tag were detected for antibody titer ,relative affinity as well as subtypes by using ELISA .The specificity of these mAb was identified by ELISA and Western blotting analysis .Double-antibody sandwich ELISA was composed of these mAb paired with the corresponding recombinant protein of specific antibody ,which was used to de-tect the recombinant protein quantitatively .Results 5 hybridoma cell lines stably secreting anti-His-tag IgG1(κ) were screened .A-mong these antibodies ,1-G2 was of the highest affinity ,reaching 1 .27 × 1010 ,which could combine with different recombinant pro-teins containing His-tag in the experiment of ELISA and Western blotting .1-G2 also could be used to detect recombinant PCT pro-tein containing His-tag quantitatively by using double-antibody sandwich ELISA with antibody of PCT ,the sensitivity of detection reached 4 .6 ng/mL .Conclusion The mAb against for His-tag with high specificity ,affinity and secreted stably are successfully prepared .This prepared antibody could be used in ELISA and Western blotting to detect a variety of His-tag .